Can tirzepatide before-and-after photos prove that it worked?

No. Two photos cannot establish what caused a change or show dose, timing, health measures, side effects, or what happened after treatment stopped. Lighting, posture, clothing, hydration, and selection can all alter the impression. Randomized trials with scheduled measurements provide a more reliable group-level timeline, though they still cannot predict one person's result.

What tends to change first on tirzepatide?

Appetite may change before a large scale change appears. In a six-week trial of 114 adults, the tirzepatide group reported lower hunger and food cravings than placebo by week 3 and ate less at a test meal. That small study describes an early group average, not a date by which every person should feel different.

When does tirzepatide weight loss usually plateau?

In a selected analysis of SURMOUNT-1 participants, the median start of a plateau ranged from 24.3 to 36.1 weeks across starting BMI groups. Researchers defined plateau as less than 5% change across a 12-week interval and every later interval, not a perfectly still scale. Dose, starting point, and individual biology can shift that timing.

Can tirzepatide affect measurements other than weight?

Yes. Tirzepatide trials measured waist circumference, blood pressure, blood sugar, insulin, lipids, and—in people with obesity and moderate-to-severe sleep apnea—breathing interruptions during sleep. These outcomes do not all move on the same schedule. Which ones matter depends on the person's condition and the monitoring plan set with a clinician.

What happens to results after stopping tirzepatide?

Regain was common in SURMOUNT-4. After an initial 36 weeks, participants switched to placebo gained an average of 14.0% of their week-36 body weight over the next year, while those continuing tirzepatide lost another 5.5%. These are group averages, not a prediction, and treatment changes belong in a prescriber conversation.

Is compounded tirzepatide an FDA-reviewed product?

No. FDA-approved versions of tirzepatide exist as branded products, but the compounded formulation offered through Promise is not FDA-approved. Compounding and branded manufacturing are different routes. A licensed provider may still prescribe a compounded formulation when appropriate; that decision is between the patient and the doctor after medical review.

Tirzepatide Before and After: An Honest Timeline

Tirzepatide before and after is better understood as a timeline than a pair of photos. In the main 72-week study, the average weight curve moved down gradually, faster early and more slowly later. Some people noticed appetite changes in the first weeks; others did not. A photo can't show dose, time, side effects, health measures, or what happened after treatment stopped.

This site does not publish before-and-after imagery. Lighting, posture, clothing, timing, and which photos are selected can make a change look larger or smaller. Here is what the studies actually measured.

Why before-and-after photos aren't evidence

Two images can show that someone looked different on two days. They can't establish why. Food intake, hydration, activity, illness, other medications, camera angle, and simple photo selection all sit outside the frame.

A randomized trial, meaning people are assigned to treatment or a comparison group by chance, answers a narrower and more reliable question. Researchers measure the same outcomes on a schedule and compare group averages. That still doesn't predict one person's experience, but it is stronger evidence than a chosen photo.

Even a scale needs context. A single reading can move with water, digestion, and time of day. The tirzepatide trials looked at trends across many months, not a dramatic morning-to-evening contrast.

Tirzepatide before and after, week by week

SURMOUNT-1, a 2022 trial of 2,539 adults with obesity or overweight and no type 2 diabetes, followed participants for 72 weeks. It included a 20-week dose-escalation period, when the studied dose rose gradually. At week 72, the group assigned to the highest maintenance dose averaged 20.9% weight reduction (Jastreboff et al., New England Journal of Medicine 2022). The full tirzepatide weight-loss results page covers the other dose groups and responder rates; this is the shape of the timeline.

Time in the study	What the published evidence shows	What it does not show
Weeks 0–4	The trial began with an initiation phase. The average curve started moving, but the main paper did not report one formal week-4 group average.	A first-month number that everyone should match.
Weeks 5–20	Dose escalation continued, and stomach-related side effects occurred mainly during this period. Weight kept trending down across the treatment groups.	That a faster increase is better; the prescriber sets the dose and pace.
Weeks 24–36	The average curve was still falling, but the slope began to ease for many participants.	That a quiet week means treatment has stopped having an effect.
Weeks 36–72	Change generally continued more slowly. A later analysis placed the median start of a plateau between 24.3 and 36.1 weeks across starting BMI groups.	One universal month when everyone reaches a final weight.

Plateau had a specific research meaning: less than 5% change over a 12-week stretch and every later 12-week stretch. It did not mean the scale never moved again. The analysis also included selected participants who took at least 75% of study doses and had reached at least 5% reduction, so its timing is a guide rather than a deadline (Horn et al., Clinical Obesity 2025).

Tirzepatide acts on GIP and GLP-1, two gut-hormone signals involved in appetite and blood sugar. Semaglutide acts on GLP-1 alone. Their milligram amounts and timelines are not interchangeable; the tirzepatide versus semaglutide comparison explains the head-to-head evidence.

What may change before the scale changes much

The early change people often call less “food noise” is not just an internet phrase, though it is not a diagnosis either. In a six-week trial of 114 adults, researchers measured appetite, cravings, hunger, and responses to food cues. By week 3, the tirzepatide group reported lower appetite and cravings than the placebo group and ate less at a test meal (Martin et al., Nature Medicine 2025). A small, short trial cannot say when—or whether—one person will notice the same thing.

Waist size, blood pressure, and lab values can move on a different schedule from body weight. A SURMOUNT-1 analysis found that blood pressure fell mainly during the first 24 weeks and then stabilized through week 72 (Krumholz et al., Heart 2024). Those measurements belong beside the scale, not underneath a photograph.

Sleep is more specific. In people who had obesity and moderate-to-severe obstructive sleep apnea, two 52-week SURMOUNT-OSA trials measured fewer breathing interruptions during sleep and better patient-reported sleep outcomes with tirzepatide than with placebo. That finding cannot be stretched into a promise that everyone will sleep better (Malhotra et al., New England Journal of Medicine 2024).

As of September 9, 2026, the day this article was written, the FDA's August 27 supplemental letter added a cardiovascular risk-reduction indication to branded Mounjaro for adults with type 2 diabetes at high risk for those events, and updated diabetic-retinopathy language from the same trial (FDA supplement letter). That is important medical context, not a visible result, and it applies to a defined population.

What the studies cannot confirm

Online posts often credit tirzepatide for a changed face, different energy, better mood, or a new reaction to certain foods. The controlled trials did not define a standard “tirzepatide face” or use casual selfies as an outcome. They also cannot separate the medication from sleep, food, activity, and other care in one person's post.

Side effects can shape the early months more than weight does. Nausea, diarrhea, constipation, or fatigue may change eating and daily routines, especially while the dose is changing. The tirzepatide side-effects guide explains that pattern without treating discomfort as proof that the medication is working.

What happens after tirzepatide stops

SURMOUNT-4 studied the “after” that photos usually leave out. Everyone first received tirzepatide for 36 weeks. Then 670 participants were assigned either to continue or switch to placebo for another year. From week 36 to week 88, the switch group regained an average of 14.0% of its week-36 body weight, while the continuing group lost another 5.5% (Aronne et al., JAMA 2024).

A 2026 follow-up analysis found that greater regain generally traveled with a greater reversal in waist circumference, blood pressure, cholesterol, blood sugar, and fasting insulin (Horn et al., JAMA Internal Medicine 2026). This does not mean every person returns to baseline. It means a treatment-period photo cannot answer what happens later. The fuller withdrawal timeline is in what happens when tirzepatide stops.

A more honest way to judge change

A useful record compares consistent scale measurements over several weeks, waist circumference taken the same way, relevant blood pressure or lab readings, sleep-apnea measures when applicable, and side effects that affect daily life. None needs a flattering angle.

Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.

The honest before-and-after is not a reveal. It is a dated record of what changed, what did not, and how the medical picture moved over time. The same week-by-week reading for the other GLP-1 is in semaglutide before and after.